Chimeric Antigen Receptor T Cell Therapy: How CAR-T Works, What It Treats, and What to Expect

What Is Chimeric Antigen Receptor T Cell Therapy

Chimeric antigen receptor T cell therapy, commonly called CAR-T, is a type of immunotherapy that changes a patient's own T cells so they can recognize and attack cancer cells. Doctors collect T cells from the blood, add a synthetic receptor that targets a specific protein on tumor cells, grow billions of copies in the lab, and return them to the patient's bloodstream. Unlike pills or infusions that circulate throughout the body, CAR-T cells are living drugs that can multiply inside the body and persist for months or years.

How CAR-T Cells Are Made

The process starts with a procedure called leukapheresis, where blood is drawn through a vein, T cells are separated, and the rest of the blood is returned. In the lab, the cells are genetically engineered using a viral vector to insert the chimeric antigen receptor gene. The receptor combines parts from different molecules so it can bind directly to a cancer cell surface protein without needing the major histocompatibility complex presentation that natural T cell receptors require. After quality testing, the patient receives lymphodepleting chemotherapy to clear space in the immune system, and the CAR-T cells are infused back.

What Cancers CAR-T Therapy Treats

Currently, approved CAR-T products target CD19, a protein found on B cell malignancies, or BCMA, a protein on plasma cells. These therapies are used mainly for blood cancers that have returned or did not respond to prior treatment. Common indications include certain types of diffuse large B cell lymphoma, mantle cell lymphoma, follicular lymphoma, B cell acute lymphoblastic leukemia, and multiple myeloma. Several products are also being studied in earlier lines of therapy and in solid tumors, though solid tumor CAR-T has faced challenges including tumor microenvironment barriers, antigen escape, and difficulty trafficking into dense tumor tissue.

The Treatment Experience

Because CAR-T is a one-time infusion given in a specialized center, patients are monitored closely for several weeks after treatment. The hospital stay usually lasts days to a couple of weeks, depending on how the cells react. Before the infusion, patients go through lymphodepleting chemotherapy, which temporarily lowers other immune cells so the CAR-T cells can expand more effectively. After infusion, doctors track cell expansion and check for side effects, with regular blood tests and clinical assessments for at least a month.

Side Effects and Safety Considerations

The most serious side effects include cytokine release syndrome and neurotoxicity, also called immune effector cell-associated neurotoxicity syndrome. Cytokine release syndrome causes fever, low blood pressure, and sometimes low oxygen levels, driven by a rapid release of inflammatory molecules as CAR-T cells activate. Neurotoxicity can lead to confusion, difficulty speaking, tremors, or seizures, though most cases improve with supportive care and medications such as tocilizumab or corticosteroids. Other risks include B cell aplasia, which increases infection risk, prolonged cytopenias, and secondary malignancies, which regulators have flagged in some treated patients.

Efficacy and Durability

In clinical trials, CAR-T therapies have produced high rates of complete remission in heavily pretreated patients, with some individuals remaining in remission for years. Durable responses are more common when minimal residual disease is undetectable after treatment. However, not all patients respond, and some relapse months or years later, sometimes because the tumor loses the target antigen or because the CAR-T cells lose function over time. Researchers are studying strategies to improve persistence, combine CAR-T with other agents, and engineer cells that target multiple antigens at once.

Current Limitations and Ongoing Research

CAR-T therapy is expensive, often costing several hundred thousand dollars, and availability is limited to specialized centers with experience managing complex immune side effects. Manufacturing takes several weeks, which can delay treatment for patients who are worsening quickly. In solid tumors, CAR-T has shown limited success so far, prompting work on armored CARs that resist immunosuppressive signals, logic-gated CARs that require two antigens to activate, and approaches that combine CAR-T with checkpoint inhibitors or other immunotherapies to improve tumor penetration and persistence.